Annovis Bio, Inc. (ANVS)
After hours:
| Previous close | 6.11 |
| Open | 6.20 |
| Bid | 5.53 x 3200 |
| Ask | 5.56 x 800 |
| Day's range | 5.45 - 6.20 |
| 52-week range | 5.23 - 22.49 |
| Volume | |
| Avg. volume | 437,868 |
| Market cap | 60.067M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as compared to 0.3 for placebo, consistent with our previous Phase II AD/PD and Discover studies Plasma Tau protein levels are reduced, consistent with our previous Phase II biomarker dataBased on the findings of this symptomatic study, Annovis plans to conduct a pivotal disease-modifying
- GlobeNewswire
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results. Fourth Quarter 2023 Highlights Clinical Updates Announced Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease (PD) On December 5, 2023, the Company
- GlobeNewswire
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
Further look at earlier Phase 1b study by ADCS unveils confirmatory data MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced the publication of new data from an earlier study supporting buntanetap as a translational inhibitor of amyloid precursor protein (APP) in patients with early Alzheimer’s Disease (AD). Buntanetap is an oral molecule that selectively
